Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.
Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) in connection with the proposed merger between Progenics and Lantheus Holdings, Inc. The lawsuit seeks damages and/or equitable relief on behalf of Progenics shareholders under the federal securities laws.
NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has enter